These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16620466)

  • 41. [Summary of a round table discussion on the therapy of optic nerve neuritis].
    Aulhorn E; Hennerici M; Kampik A; Schmidt D; Schmidt R; Friedburg D
    Fortschr Ophthalmol; 1983; 80(5):369-70. PubMed ID: 6642355
    [No Abstract]   [Full Text] [Related]  

  • 42. Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal.
    Dastgir J; DiMario FJ
    J Child Neurol; 2009 Apr; 24(4):431-7. PubMed ID: 19189932
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute multiple sclerosis characterized by extensive mononuclear phagocyte infiltration.
    Shields DC; Avgeropoulos NG; Banik NL; Tyor WR
    Neurochem Res; 2000 Nov; 25(11):1517-20. PubMed ID: 11071372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Therapeutic aspects of multiple sclerosis].
    Gonsette RE
    Bull Soc Belge Ophtalmol; 1982; 199-200():275-80. PubMed ID: 7184504
    [No Abstract]   [Full Text] [Related]  

  • 45. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
    Seres E; Vécsei L
    Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The treatment of multiple sclerosis.
    Kott HS
    Med Clin North Am; 1972 May; 56(3):711-6. PubMed ID: 4338391
    [No Abstract]   [Full Text] [Related]  

  • 47. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
    Gout O
    Ann Neurol; 2008 Jan; 63(1):126; author reply 126-7. PubMed ID: 17702028
    [No Abstract]   [Full Text] [Related]  

  • 48. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The efficiency of various treatment methods in multiple sclerosis.
    Cincă I; Popa C; Ticmeanu M
    Neurol Psychiatr (Bucur); 1977; 15(4):249-62. PubMed ID: 601473
    [No Abstract]   [Full Text] [Related]  

  • 50. [Modern therapeutic viewpoints in the treatment of multiple sclerosis].
    Neumayer E
    Wien Med Wochenschr; 1969 Apr; 119(15):281-4. PubMed ID: 5769603
    [No Abstract]   [Full Text] [Related]  

  • 51. Treatment and prevention of myelin disorders: multiple sclerosis.
    Abramsky O
    Bull Soc Belge Ophtalmol; 1983 Nov; 208 Pt 1():489-92. PubMed ID: 6326915
    [No Abstract]   [Full Text] [Related]  

  • 52. Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis.
    Lage MJ; Castelli-Haley J; Oleen-Burkey MA
    Work; 2006; 27(2):143-51. PubMed ID: 16971761
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The treatment of multiple sclerosis with beta-interferon.
    Poser CM
    Neuroepidemiology; 2008; 31(3):157-8. PubMed ID: 18716413
    [No Abstract]   [Full Text] [Related]  

  • 54. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
    [No Abstract]   [Full Text] [Related]  

  • 55. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treatment of multiple sclerosis: current opinion].
    Yamamura T
    No To Shinkei; 2001 Aug; 53(8):707-13. PubMed ID: 11577411
    [No Abstract]   [Full Text] [Related]  

  • 57. Interferon beta in multiple sclerosis. Current policy is sensible.
    Price C
    BMJ; 1997 Feb; 314(7080):600-1. PubMed ID: 9055728
    [No Abstract]   [Full Text] [Related]  

  • 58. Intravenous immunoglobulin, plasmalymphocytapheresis and azathioprine in chronic progressive multiple sclerosis.
    Uccelli A; Capello E; Fenoglio D; Incagliato M; Valbonesi M; Mancardi GL
    Ital J Neurol Sci; 1994 Feb; 15(1):51-3. PubMed ID: 8206747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Should neutralizing antibodies be monitored during interferon-beta treatment for multiple sclerosis?
    Oger J; Gibbs E
    Nat Clin Pract Neurol; 2006 Feb; 2(2):76-7. PubMed ID: 16932528
    [No Abstract]   [Full Text] [Related]  

  • 60. [Multiple sclerosis].
    Igata A
    Nihon Rinsho; 1970 Jul; 28(7):1886-91. PubMed ID: 4918043
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.